Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure
Med rev
; 11(4)2009.
Article
em En
| CUMED
| ID: cum-42155
Biblioteca responsável:
CU1.1
ABSTRACT
Previous studies have shown that an epidermal growth factor-based formulation (Heberprot-P) can enhance granulation of high-grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to complete wound closure. A pilot study in 20 diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution was performed. Mean ulcer size was 16,3 ± 21,3 cm2. Intralesional injections of 75 ìg of Heberprot-P three times per week were given up to complete wound healing...(AU)
Texto completo:
1
Coleções:
06-national
/
CU
Base de dados:
CUMED
Assunto principal:
Diabetes Mellitus
Limite:
Humans
Idioma:
En
Revista:
Med rev
Ano de publicação:
2009
Tipo de documento:
Article